Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Other financing activities: 2014-2022

Historic Other financing activities for Viking Therapeutics (VKTX) over the last 9 years, with Dec 2022 value amounting to $22,000.

  • Viking Therapeutics' Other financing activities was N/A to $37,000 in Q1 2023 from the same period last year, while for Mar 2023 it was $346,000, marking a year-over-year change of. This contributed to the annual value of $22,000 for FY2022, which is 52.17% down from last year.
  • Per Viking Therapeutics' latest filing, its Other financing activities stood at $22,000 for FY2022, which was down 52.17% from $46,000 recorded in FY2021.
  • In the past 5 years, Viking Therapeutics' Other financing activities registered a high of $765,000 during FY2018, and its lowest value of $22,000 during FY2022.
  • Over the past 3 years, Viking Therapeutics' median Other financing activities value was $26,000 (recorded in 2020), while the average stood at $31,333.
  • As far as peak fluctuations go, Viking Therapeutics' Other financing activities plummeted by 90.46% in 2019, and later spiked by 76.92% in 2021.
  • Over the past 5 years, Viking Therapeutics' Other financing activities (Yearly) stood at $765,000 in 2018, then crashed by 90.46% to $73,000 in 2019, then crashed by 64.38% to $26,000 in 2020, then skyrocketed by 76.92% to $46,000 in 2021, then tumbled by 52.17% to $22,000 in 2022.